Developing an Opioid Taper Intervention Before Total Joint Arthroplasty
Developing and Testing an Opioid Taper Intervention Before Total Knee Arthroplasty: Phase 2 Intervention Development
University of Alabama at Birmingham
45 participants
Jan 10, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
Eligibility
Inclusion Criteria4
- decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks
- currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months
- have a reliable telephone number for contact
- speaks English
Exclusion Criteria5
- Taking opioid medications that include:
- Buprenorphine
- Methadone
- Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)
- Transdermal formations of opioid pain medications (e.g., fentanyl patches)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The participant will attempt to taper their opioid dose by \~50% during the 4-6 week preoperative period
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05788016